Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).

Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 04; 11(4):e004745.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Aminobutyrates
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Biphenyl Compounds
Drug Combinations
Enalapril
Female
Heart Failure
Humans
Hypotension
Incidence
Male
Middle Aged
Neprilysin
Prospective Studies
Stroke Volume
Tetrazoles
Treatment Outcome
Valsartan

authors with profiles

Michael R. Zile